ENO1 and cancer: Taken together, we focused on these two cancer cell lines and proposed an antibody-based drug combination therapy, that is, the anti-ENO1 antibody combined with MET could reverse drug resistance caused by CSCs in conventional treatments (DDP or CTX), and preliminarily explored the mechanism.